Restoring tumor immunogenicity with dendritic cell reprogramming
Science Immunology · 28.07.2023 · 8 (85)
DOI: 10.1126/sciimmunol.add4817 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Immunology, erschienen am 28.07.2023. Verfasst von Olga Zimmermannova und 28 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Medicine and Gene Therapy, Lund Stem Cell Centre, Lund University, BMC A12, 221 84 Lund, Sweden. Hauptthemen laut MEDLINE: CD8-Positive T-Lymphocytes, Melanoma. Die Arbeit wurde bisher 94-mal zitiert (Crossref) und nennt 83 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: European Research Council.
Abstract (Originalsprache)
Decreased antigen presentation contributes to the ability of cancer cells to evade the immune system. We used the minimal gene regulatory network of type 1 conventional dendritic cells (cDC1) to reprogram cancer cells into professional antigen-presenting cells (tumor-APCs). Enforced expression of the transcription factors PU.1, IRF8, and BATF3 (PIB) was sufficient to induce the cDC1 phenotype in 36 cell lines derived from human and mouse hematological and solid tumors. Within 9 days of reprogramming, tumor-APCs acquired transcriptional and epigenetic programs associated with cDC1 cells. Reprogramming restored the expression of antigen presentation complexes and costimulatory molecules on the surfaces of tumor cells, allowing the presentation of endogenous tumor antigens on MHC-I and facilitating targeted killing by CD8 + T cells. Functionally, tumor-APCs engulfed and processed proteins and dead cells, secreted inflammatory cytokines, and cross-presented antigens to naïve CD8 + T cells. Human primary tumor cells could also be reprogrammed to increase their capability to present antigen and to activate patient-specific tumor-infiltrating lymphocytes. In addition to acquiring improved antigen presentation, tumor-APCs had impaired tumorigenicity in vitro and in vivo. Injection of in vitro generated melanoma-derived tumor-APCs into subcutaneous melanoma tumors delayed tumor growth and increased survival in mice. Antitumor immunity elicited by tumor-APCs was synergistic with immune checkpoint inhibitors. Our approach serves as a platform for the development of immunotherapies that endow cancer cells with the capability to process and present endogenous tumor antigens.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Molecular Medicine and Gene Therapy, Lund Stem Cell Centre, Lund University, BMC A12, 221 84 Lund, Sweden.
- Wallenberg Center for Molecular Medicine at Lund University, BMC A12, 221 84 Lund, Sweden.
- CNC-Centre for Neuroscience and Cell Biology, University of Coimbra, Largo Marquês do Pombal, 3004-517 Coimbra, Portugal.
- Doctoral Programme in Experimental Biology and Biomedicine, University of Coimbra, Largo Marquês do Pombal, 3004-517 Coimbra, Portugal.
- National Center of Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Borgmester Ib Juuls Vej 1, 2730 Herlev, Denmark.
- Department of Health Technology, Technical University of Denmark, Ørsteds Pl. 345C, 2800 Kongens Lyngby, Denmark.
ORCID-Profile: Olga Zimmermannova, Alexandra G Ferreira, Ervin Ascic, Marta Velasco Santiago, Ilia Kurochkin, Morten Hansen, Özcan Met, Inês Caiado, Marion Humbert, Diego Soto-Cabrera, Hreinn Benonisson, David Gomez-Jimenez, Carina Bernardo, Monika Bauden, Roland Andersson, Kenichi Miharada, Yukio Nakamura, Stephanie Hugues, Lennart Greiff, Malin Lindstedt, Fábio F Rosa, Cristiana F Pires, Michal Bassani-Sternberg, Inge Marie Svane, Carlos-Filipe Pereira
Förderung
- European Research Council
Zitieren
APA
Zimmermannova, O., Ferreira, A. G., Ascic, E., Velasco Santiago, M., Kurochkin, I., Hansen, M., Met, Ö., Caiado, I., Shapiro, I. E., Michaux, J., Humbert, M., Soto-Cabrera, D., Benonisson, H., Silvério-Alves, R., Gomez-Jimenez, D., Bernardo, C., Bauden, M., Andersson, R., Höglund, M., …, & Pereira, C. F. (2023). Restoring tumor immunogenicity with dendritic cell reprogramming. Science Immunology, 8(85). https://doi.org/10.1126/sciimmunol.add4817
Vancouver
Zimmermannova O, Ferreira AG, Ascic E, Velasco Santiago M, Kurochkin I, Hansen M, et al. Restoring tumor immunogenicity with dendritic cell reprogramming. Science Immunology. 2023;8(85). doi:10.1126/sciimmunol.add4817
BibTeX
@article{Zimmermannova2023,
author = {Zimmermannova, Olga and Ferreira, Alexandra G and Ascic, Ervin and Velasco Santiago, Marta and Kurochkin, Ilia and Hansen, Morten and Met, Özcan and Caiado, Inês and Shapiro, Ilja E and Michaux, Justine and Humbert, Marion and Soto-Cabrera, Diego and Benonisson, Hreinn and Silvério-Alves, Rita and Gomez-Jimenez, David and Bernardo, Carina and Bauden, Monika and Andersson, Roland and Höglund, Mattias and Miharada, Kenichi and Nakamura, Yukio and Hugues, Stephanie and Greiff, Lennart and Lindstedt, Malin and Rosa, Fábio F and Pires, Cristiana F and Bassani-Sternberg, Michal and Svane, Inge Marie and Pereira, Carlos-Filipe},
title = {Restoring tumor immunogenicity with dendritic cell reprogramming},
journal = {Science Immunology},
year = {2023},
volume = {8},
number = {85},
doi = {10.1126/sciimmunol.add4817}
}
EUVIMED